File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women

TitleComparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women
Authors
Issue Date2007
PublisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/00774/index.htm
Citation
Journal Of Bone And Mineral Metabolism, 2007, v. 25 n. 2, p. 105-113 How to Cite?
AbstractWe evaluated adherence with raloxifene therapy compared with daily bisphosphonate in Asian postmenopausal women at increased risk of osteoporotic fractures. In this 12-month observational study conducted in Asia (Hong Kong, Malaysia, Pakistan, Philippines, Singapore, Taiwan), 984 postmenopausal women (aged 55 years or older) were treated with raloxifene 60 mg/day (n = 707; 72%) or daily bisphosphonate (alendronate 10 mg/day; n = 206; 21%, or risedronate 5 mg/day; n = 71; 7%) during their normal course of care. Patients were assessed at baseline, 6, and 12 months. Baseline characteristics (including age, race, education, menopausal status, and baseline fractures) were comparable between the raloxifene and bisphosphonate groups. More women on raloxifene completed the study compared with those on bisphosphonate (50.2% versus 37.5%; P < 0.001). Patients also took raloxifene for a longer period than bisphosphonate (median, 356 versus 348 days; P = 0.011). Compared with those taking bisphosphonate, significantly fewer patients taking raloxifene discontinued the study because of stopping treatment (5.7% versus 10.1%, P = 0.017) or changing treatment (2.8% versus 9.7%, P < 0.001). Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6.9%) bisphosphonate patients compared with 0 raloxifene patients. The percentage of patients who had consumed 80% or more of their study medication was similar for raloxifene patients (48-56 weeks; 95.2%) and bisphosphonate patients (48-56 weeks; 93.3%). More raloxifene patients responded that they were satisfied with their medication than bisphosphonate patients at 48-56 weeks (P = 0.002). We concluded that Asian postmenopausal women at increased risk of osteoporotic fractures showed a greater propensity to remain on raloxifene compared with bisphosphonate. The women on raloxifene exhibited lower discontinuation rates and higher treatment satisfaction. © 2007 Springer-Verlag.
Persistent Identifierhttp://hdl.handle.net/10722/78150
ISSN
2015 Impact Factor: 2.312
2015 SCImago Journal Rankings: 0.775
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPasion, EGen_HK
dc.contributor.authorSivananthan, SKen_HK
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorChen, SHen_HK
dc.contributor.authorChen, YJen_HK
dc.contributor.authorMirasol, Ren_HK
dc.contributor.authorTay, BKen_HK
dc.contributor.authorShah, GAen_HK
dc.contributor.authorKhan, MAen_HK
dc.contributor.authorTam, Fen_HK
dc.contributor.authorHall, BJen_HK
dc.contributor.authorThiebaud, Den_HK
dc.date.accessioned2010-09-06T07:39:43Z-
dc.date.available2010-09-06T07:39:43Z-
dc.date.issued2007en_HK
dc.identifier.citationJournal Of Bone And Mineral Metabolism, 2007, v. 25 n. 2, p. 105-113en_HK
dc.identifier.issn0914-8779en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78150-
dc.description.abstractWe evaluated adherence with raloxifene therapy compared with daily bisphosphonate in Asian postmenopausal women at increased risk of osteoporotic fractures. In this 12-month observational study conducted in Asia (Hong Kong, Malaysia, Pakistan, Philippines, Singapore, Taiwan), 984 postmenopausal women (aged 55 years or older) were treated with raloxifene 60 mg/day (n = 707; 72%) or daily bisphosphonate (alendronate 10 mg/day; n = 206; 21%, or risedronate 5 mg/day; n = 71; 7%) during their normal course of care. Patients were assessed at baseline, 6, and 12 months. Baseline characteristics (including age, race, education, menopausal status, and baseline fractures) were comparable between the raloxifene and bisphosphonate groups. More women on raloxifene completed the study compared with those on bisphosphonate (50.2% versus 37.5%; P < 0.001). Patients also took raloxifene for a longer period than bisphosphonate (median, 356 versus 348 days; P = 0.011). Compared with those taking bisphosphonate, significantly fewer patients taking raloxifene discontinued the study because of stopping treatment (5.7% versus 10.1%, P = 0.017) or changing treatment (2.8% versus 9.7%, P < 0.001). Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6.9%) bisphosphonate patients compared with 0 raloxifene patients. The percentage of patients who had consumed 80% or more of their study medication was similar for raloxifene patients (48-56 weeks; 95.2%) and bisphosphonate patients (48-56 weeks; 93.3%). More raloxifene patients responded that they were satisfied with their medication than bisphosphonate patients at 48-56 weeks (P = 0.002). We concluded that Asian postmenopausal women at increased risk of osteoporotic fractures showed a greater propensity to remain on raloxifene compared with bisphosphonate. The women on raloxifene exhibited lower discontinuation rates and higher treatment satisfaction. © 2007 Springer-Verlag.en_HK
dc.languageengen_HK
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/00774/index.htmen_HK
dc.relation.ispartofJournal of Bone and Mineral Metabolismen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAlendronate - therapeutic useen_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshBone Densityen_HK
dc.subject.meshBone Density Conservation Agents - therapeutic useen_HK
dc.subject.meshEtidronic Acid - analogs & derivatives - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOsteoporosis, Postmenopausal - prevention & controlen_HK
dc.subject.meshPatient Complianceen_HK
dc.subject.meshPatient Satisfactionen_HK
dc.subject.meshPostmenopauseen_HK
dc.subject.meshQuestionnairesen_HK
dc.subject.meshRaloxifene - therapeutic useen_HK
dc.titleComparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian womenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0884-0431&volume=25&spage=105&epage=13&date=2007&atitle=Comparison+of+raloxifene+and+bisphosphonates+based+on+adherence+and+treatment+satisfaction+in+postmenopausal+Asian+womenen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00774-006-0735-7en_HK
dc.identifier.pmid17323180-
dc.identifier.scopuseid_2-s2.0-33847311328en_HK
dc.identifier.hkuros131077en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33847311328&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume25en_HK
dc.identifier.issue2en_HK
dc.identifier.spage105en_HK
dc.identifier.epage113en_HK
dc.identifier.isiWOS:000244507200005-
dc.publisher.placeJapanen_HK
dc.identifier.scopusauthoridPasion, EG=6505876740en_HK
dc.identifier.scopusauthoridSivananthan, SK=16022838400en_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridChen, SH=7410263412en_HK
dc.identifier.scopusauthoridChen, YJ=23569155400en_HK
dc.identifier.scopusauthoridMirasol, R=16022245900en_HK
dc.identifier.scopusauthoridTay, BK=7101924558en_HK
dc.identifier.scopusauthoridShah, GA=16022775900en_HK
dc.identifier.scopusauthoridKhan, MA=37036517900en_HK
dc.identifier.scopusauthoridTam, F=16023314900en_HK
dc.identifier.scopusauthoridHall, BJ=8333458900en_HK
dc.identifier.scopusauthoridThiebaud, D=7005184974en_HK
dc.identifier.citeulike1189791-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats